Spero Therapeutics (NASDAQ:SPRO) Rating Lowered to “Sell” at Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 target price for the company. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Weiss Ratings cut Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Finally, HC Wainwright increased their price target on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO opened at $1.06 on Friday. The business has a fifty day moving average of $1.17 and a two-hundred day moving average of $1.98. The stock has a market cap of $61.73 million, a P/E ratio of 9.64 and a beta of 1.59. Spero Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.08.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, equities analysts anticipate that Spero Therapeutics will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Spero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC bought a new stake in shares of Spero Therapeutics during the second quarter worth about $36,000. Global Retirement Partners LLC purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at $55,000. GSA Capital Partners LLP purchased a new stake in Spero Therapeutics in the second quarter valued at approximately $632,000. BlackRock Inc. bought a new stake in Spero Therapeutics during the second quarter worth about $1,314,000. Finally, Alphabet Inc. bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $1,967,000. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.